Texas Dream Act allowing in-state tuition for undocumented students dismantled
"All three of my brothers and sisters are college graduates. We made it, but we are a very small percentage of people who, because of HB 1403, because of in-state tuition, were able to make it," said Cesar Espinosa, a Texas Dream Act recipient.
Wednesday, just hours after the Department of Justice filed suit challenging the Texas law, a federal judge blocked the Texas Dream Act, calling it "unconstitutional and invalid."
The law was passed in the state legislature in 2001 with bipartisan support.
Domingo Garcia who was a state representative at the time and helped write the bill is calling this latest development "mean-spirited."
"The recent remarks and actions targeting the Hispanic community in Texas are deeply concerning and do not reflect the values of fairness, justice, and equality that our society is built upon," said Garcia.
There have been efforts in the legislature to eliminate the Texas Dream Act. In April, Espinosa was one of dozens of people who testified against a bill to tear it down.
"It took me 33 years to get my status. I wanted to get status when I was 5, I wanted to get status when I was 10, I was dying to get status when I was 18 and was accepted to Yale, and Brown and Cornell University," said Espinosa.
Many are also highlighting the economic consequences this repeal will bring.
According to a report by Every Texan, Texas Dream Act students paid $81.6 million in tuition and fees in 2023.
"The Texas Dream Act is one of the rare pieces of legislation that over 20 years people who have tried to come and mess with it have failed because it was designed so well to do what it was supposed to do what it was supposed to do, which is recoup the investment that we make on students," said Jaime Puente, Director of Economic opportunity, Every Texan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
5 minutes ago
- Fox News
Analyzing fallout from American Eagle's Sydney Sweeney ad campaign
Fox News contributor Katrina Campins, Fox News political analyst Gianno Caldwell and comedian Danny Polishchuk join 'Fox News Saturday Night' to discuss.
Yahoo
10 minutes ago
- Yahoo
In draft congressional map, Texas Republicans bet big that gains with Latino voters will persist
WASHINGTON — In the 2024 election, Hispanic voters fled their traditional Democratic Party roots, casting their ballots for Republican Donald Trump at historic rates in areas long seen as Democratic strongholds, like South Texas. With their plan to flip five blue seats under a new congressional map introduced in the Legislature last week, Texas Republicans are betting Latino voters will stick with them in 2026. In three of the districts Republicans hope to capture — the 9th Congressional District in east Houston, the 35th District southeast of San Antonio and Rep. Henry Cuellar's 28th District in South Texas — the GOP map-drawers crafted new boundaries that make each seat more favorable for Republicans while also adding more Hispanic voters to the district. These three districts would be majority Hispanic, as would the seat held by Rep. Vicente Gonzalez, D-McAllen, whose South Texas seat Republicans are also gunning for. If the districts were in place during the 2024 election, Trump would have carried each by at least 10 percentage points, according to a Texas Tribune analysis. Such margins depended, in large part, on Hispanic-majority counties whose voters have been moving rightward since 2016. And in 2024, when the vast majority of U.S. counties shifted right, predominantly Hispanic counties saw even more pronounced movement. Trump carried all four counties in the Rio Grande Valley after failing to crack 30% in the region during his first presidential bid, and he won 14 of the 18 Texas counties within 20 miles of the border. But Trump's coattails extended only so far down the ballot, with Democrats winning numerous local races in the same counties that recorded eye-popping shifts at the top of the ticket. Cuellar and Gonzalez secured reelection even as Trump carried their districts, and even with Cuellar also facing down an indictment for alleged money laundering and bribery. GOP Sen. Ted Cruz, appearing just below Trump on November ballots, ran well behind his party's nominee in a number of South Texas locales, especially those with larger Latino populations. If the new lines proposed for Cuellar's district had been in place, the 28th District would have gone for Trump by 10 points, while Cruz would have eked out a narrow 0.1% win. Without Trump at the top of the ticket in 2026 and three of the five target districts increasing their share of Hispanic voters, the GOP map-drawers are making what could amount to a risky bet that enough Latino voters will turn out again to support GOP candidates across the ballot. Chuck Rocha, a Democratic strategist who has worked in Texas politics for decades and hosts a podcast about Latino voters, believes Trump has a unique appeal to Hispanic voters that doesn't necessarily trickle down to other Republican candidates. Especially potent was Trump's assertion that the economic system was rigged against Americans and he would be the one to fix it, Rocha said. That sort of messaging transcends partisan affiliation, Rocha said, arguing that Trump in 2024 and progressive Sen. Bernie Sanders in 2020 each overperformed in the Rio Grande Valley and with Latino voters 'because their messages aligned around a rigged system, around failed trade policies and reinvigorating economic populism.' 'The newest swingy electorate in Texas' Trump's freewheeling lack of political correctness also led some Hispanic voters to associate him with 'machismo,' Gilberto Hinojosa, the former Texas Democratic Party chair and Cameron County judge, said. 'In some parts of our community, they could relate to that.' Campaign operatives from both parties pinpointed two issues that drove Latino voters to the right last November: immigration and the economy. During the campaign, those operatives told the Tribune, President Joe Biden and Democrats struggled to convince voters they were doing enough to secure the southern border, while inflation hit the electorate's pocketbooks and proved an especially damaging issue for Democratic presidential nominee Kamala Harris among Hispanic voters. 'Four years of open borders and 12 million illegal immigrants coming into this country did real damage across Texas, but in the Hispanic community in particular,' Cruz told The Texas Tribune last week. 'I think that was a big part of the reason why both President Trump and I won Hispanics statewide, and why the two of us flipped the Rio Grande Valley.' But Rocha doesn't think this means Trump and other Republicans are sure to hold onto those gains with Latino voters, who he labeled 'the newest swingy electorate in Texas.' Trump's approval rating is underwater among Hispanic voters. A July national poll by Equis Research found that one-third of Hispanic voters who backed Biden in 2020 then Trump in 2024 are planning to vote for a Democratic congressional candidate. Another one-third of these voters are undecided. Democrats are gearing up to court Latino voters in next year's midterms by homing in on the economy, already deploying messaging that highlights Trump's tariff strategy — which many economists have said will worsen inflation — to paint Republicans as unconcerned with the day-to-day lives of Americans. 'Throughout this cycle Democrats will be laser focused on making sure Latino voters know the harm that has come from the Republican trifecta and highlighting how Republicans broke their promise to lower costs and instead gave billionaires a tax cut at their communities' expense,' said Madison Andrus, a spokesperson for the Democratic Congressional Campaign Committee, House Democrats' campaign arm. Republicans largely believe they can outflank Democrats by simply reminding voters of the record-high inflation under Biden's presidency. Prices for some common goods have fallen since Trump returned to the White House, a fact that GOP operative Wayne Hamilton sees as a bulwark against a Democratic resurgence among Latinos. 'Long term, that's good for South Texas,' said Hamilton, who leads a group, Project Red TX, that focuses on recruiting and supporting Republican candidates in South Texas. 'That's good for the border. That's good for America.' Jobs are also likely to be central to any messaging to Latino voters. In South Texas, many Hispanic voters work in the fracking industry — a sector some Democrats want to phase out in favor of clean energy alternatives. That plan, Hinojosa said, is viewed by Latinos as an existential threat to their jobs and way of life, despite the employment opportunities also generated by renewable energy. 'What's important to Hispanics in South Texas is quality jobs that provide good wages and working conditions and benefits,' Hinojosa said. Rocha agreed, arguing that Democrats should run ads centered on the 'sanctity of work.' On the other side of the aisle, Republicans are looking to do the same. To win Hispanic voters, Cruz said Republicans need to 'remain the party of jobs,' calling it his 'No. 1 priority in the Senate.' The National Republican Campaign Committee is also recruiting Latino candidates to run in districts that could tilt in their favor if new Texas maps are approved. Gonzalez has drawn a challenge from Eric Flores, a Republican Army veteran and lawyer from Mission, while Cuellar may face Democrat-turned-Republican Webb County Judge Tano Tijerina, who is mulling a race. 'Hispanic communities in South Texas are sick and tired of out of touch Democrats Henry Cuellar and Vicente Gonzalez turning their backs on them time and again,' NRCC spokesperson Zach Bannon said in a statement. Mayra Flores, a Republican who briefly represented the 34th District after winning a 2022 special election for part of 2022, has already announced a bid against Cuellar. The lineup for The Texas Tribune Festival continues to grow! Be there when all-star leaders, innovators and newsmakers take the stage in downtown Austin, Nov. 13–15. The newest additions include comedian, actor and writer John Mulaney; Dallas mayor Eric Johnson; U.S. Sen. Amy Klobuchar, D-Minnesota; New York Media Editor-at-Large Kara Swisher; and U.S. Rep. Veronica Escobar, D-El Paso. Get your tickets today! TribFest 2025 is presented by JPMorganChase.
